Finance

Beta
Lists
RAD:ASX
Radiopharm Theranostics Ltd
A$0.020
+5.26%
(+0.0010) 1D
Jun 5, 4:10:02 PM GMT+10  ·   AUD
All symbols
SymbolPriceChange% Change
Generating top insights for RAD...
Open
A$0.02
High
A$0.02
Low
A$0.02
Mkt. cap
67.34M
Avg. vol.
1.63M
Volume
4.68M
52-wk high
A$0.04
52-wk low
A$0.02
EPS
-A$0.02
Shares outstanding
3.54B
No. of employees
14
Open
A$0.02
High
A$0.02
Low
A$0.02
Mkt. cap
67.34M
Avg. vol.
1.63M
Volume
4.68M
52-wk high
A$0.04
52-wk low
A$0.02
EPS
-A$0.02
Shares outstanding
3.54B
No. of employees
14
News stories
From sources across the web
About Radiopharm Theranostics Ltd
CEO-
Employees14
Founded2021
Headquarters-
SectorBiotechnology
Websiteradiopharmtheranostics.com
Last report
Jan 29, 2025
Fiscal period
Q2 2025
EPS / Est. (USD)
-$0.01 / -$0.01
+9.57%beat
Revenue / Est. (USD)
859.04K / 0.00
+∞%beat
Fiscal Q2 2025 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in AUD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
5.04M
5.04M
3.10M
3.10M
Cost of goods sold
7.95M
7.95M
11.30M
11.30M
Cost of revenue
7.95M
7.95M
11.30M
11.30M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.15M
4.15M
4.18M
4.18M
Operating expense
4.75M
4.75M
4.95M
4.95M
Total operating expenses
12.70M
12.70M
16.25M
16.25M
Operating income
-7.66M
-7.66M
-13.14M
-13.14M
Other non operating income
-143.00
-143.00
-
-
EBT including unusual items
-9.35M
-9.35M
-14.05M
-14.05M
EBT excluding unusual items
-7.54M
-7.54M
-13.37M
-13.37M
Income tax expense
1.16K
1.16K
67.15K
67.15K
Effective tax rate
-0.01%
-0.01%
-0.48%
-0.48%
Other operating expenses
-
-
-
-
Net income
-9.81M
-9.81M
-13.48M
-13.48M
Net profit margin
-194.71%
-194.71%
-434.67%
-434.67%
Earnings per share
-
-
-
-
Interest and investment income
444.10K
444.10K
-
-
Interest expense
-32.65K
-32.65K
-32.55K
-32.55K
Net interest expenses
411.45K
411.45K
-32.55K
-32.55K
Depreciation and amortization charges
-
-
-
-
EBITDA
-7.12M
-7.12M
-12.47M
-12.47M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer